Boardroom Alpha
Boardroom Alpha
KOD · Additional Proxy Materials (DEFA14A) · Filed April 22, 2026

Kodiak Sciences Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 22, 2026
Ticker
KOD
Accession
0001193125-26-170482
Boardroom Alpha · Filing insights

Kodiak Sciences Inc. filed definitive additional materials. No material governance or investor developments disclosed as of this filing.

About Kodiak Sciences Inc
Market cap
$2.1B
1Y TSR
+919.1%
3Y TSR
+69.3%
Board grade
B
Sector
Healthcare
CEO
Victor Perlroth
Last annual meeting: Jun 2, 2026 · View full Kodiak Sciences Inc profile →
DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934

(Amendment No. )

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

 

KODIAK SCIENCES INC.

img125765733_0.jpg

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1)

and 0-11

 

 


 

img125765733_1.jpg

 


 

img125765733_2.jpg

 


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Kodiak Sciences Inc (KOD)

Reference

Frequently asked questions

When did Kodiak Sciences Inc file this DEFA14A?
Kodiak Sciences Inc (KOD) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 22, 2026. The accession number assigned by EDGAR is 0001193125-26-170482.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Kodiak Sciences Inc. filed definitive additional materials. No material governance or investor developments disclosed as of this filing. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Kodiak Sciences Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Kodiak Sciences Inc has filed under CIK 1468748, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer